If you are wondering whether Novavax at around US$7.25 is a bargain or a value trap, you are not alone. This article focuses on what the current price really implies about the company. The stock has ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

Shares of Novavax (NASDAQ: NVAX), a clinical-stage vaccine company focused on developing nanoparticle and recombinant vaccines to treat and prevent a variety of diseases, tanked and fell as much as 11 ...

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports ...

The pharmaceutical company saw measurable but modest growth last quarter, but remains in the red. Its vaccine science, however, has motivated a rival drugmaker to enter into a lucrative partnership.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. Novavax (NASDAQ: NVAX) was once a leading contender to ...

With more knowledge about the virus, ample funding, and new treatments, the worst of the COVID-19 pandemic seems to be behind us (from a death perspective). However, just because the Coronavirus death ...